Dashboard
Manage Tickers

BIIBBIOGEN INC.

Nasdaq biogen.com


$ 199.25 $ -1.54 (-0.77 %)    

Monday, 09-Sep-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 199.27
$ 199.25 x 100
$ 210.03 x 100
-- - --
$ 189.44 - $ 269.43
883,333
na
29.03B
$ 0.69
$ 25.05
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 04-24-2024 03-31-2024 10-Q
3 02-14-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 07-25-2023 06-30-2023 10-Q
6 04-25-2023 03-31-2023 10-Q
7 02-15-2023 12-31-2022 10-K
8 10-25-2022 09-30-2022 10-Q
9 07-20-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-03-2022 12-31-2021 10-K
12 10-20-2021 09-30-2021 10-Q
13 07-22-2021 06-30-2021 10-Q
14 04-22-2021 03-31-2021 10-Q
15 02-03-2021 12-31-2020 10-K
16 10-21-2020 09-30-2020 10-Q
17 07-22-2020 06-30-2020 10-Q
18 04-23-2020 03-31-2020 10-Q
19 02-06-2020 12-31-2019 10-K
20 10-22-2019 09-30-2019 10-Q
21 07-24-2019 06-30-2019 10-Q
22 04-24-2019 03-31-2019 10-Q
23 02-06-2019 12-31-2018 10-K
24 10-23-2018 09-30-2018 10-Q
25 07-24-2018 06-30-2018 10-Q
26 04-24-2018 03-31-2018 10-Q
27 02-01-2018 12-31-2017 10-K
28 10-24-2017 09-30-2017 10-Q
29 07-25-2017 06-30-2017 10-Q
30 04-25-2017 03-31-2017 10-Q
31 02-02-2017 12-31-2016 10-K
32 10-26-2016 09-30-2016 10-Q
33 07-21-2016 06-30-2016 10-Q
34 04-21-2016 03-31-2016 10-Q
35 02-03-2016 12-31-2015 10-K
36 10-21-2015 09-30-2015 10-Q
37 07-24-2015 06-30-2015 10-Q
38 04-24-2015 03-31-2015 10-Q
39 02-04-2015 12-31-2014 10-K
40 10-22-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

zepbound-and-mounjaro-maker-eli-illy-has-a-new-cfo-as-it-navigates-regulatory-challenges-what-you-should-know
Zepbound And Mounjaro Maker Eli Illy Has A...
09/10/2024 03:00:59

Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediate...

bernie-sanders-says-if-youre-poor-in-america-youll-live-10-15-years-less-anybody-else-see-a-problem-with-that
Bernie Sanders Says If You're Poor In Amer...
09/10/2024 02:12:36

cantor-fitzgerald-reiterates-overweight-on-biogen-maintains-292-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:28:53

Cantor Fitzgerald analyst Eric Schmidt reiterates Biogen (NASDAQ:BIIB) with a Overweight and maintains $292 price target.

biogeneisais-leqembi-brings-hope-to-early-alzheimers-patients-amid-logistical-challenges
Biogen/Eisai's Leqembi Brings Hope To Earl...
09/09/2024 14:12:06

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highligh...

biogens-higher-dose-spinraza-shows-to-slow-neurodegeneration-faster-in-infants-with-rare-neuromuscular-disorder
Biogen's Higher Dose Spinraza Shows To Slo...
09/04/2024 14:43:28

Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor ...

key-takeaways-from-biogen-analyst-ratings
Key Takeaways From Biogen Analyst Ratings
09/04/2024 13:00:55

biogen-announces-data-for-higher-dose-nusinersen-in-infants-with-spinal-muscular-atrophy
Biogen Announces Data for Higher Dose Nusi...
09/04/2024 11:33:42

Biogen Inc. (NASDAQ:BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study...

needham-reiterates-buy-on-biogen-maintains-285-price-target
Needham Reiterates Buy on Biogen, Maintain...
09/04/2024 10:25:26

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.

eli-lilly-is-the-nvidia-of-weight-loss-and-glp-1-space-says-roundhill-investments-ceo-emphasizes-market-leadership-and-growth-potential-of-zepbound-maker
Eli Lilly Is The Nvidia Of Weight Loss And...
08/28/2024 08:21:26

Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.

chinese-e-commerce-giant-drops-35-in-2-days-but-analysts-see-92-upside-potential
Chinese E-Commerce Giant Drops 35% In 2 Da...
08/27/2024 20:56:47

PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets r...

eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safety
Eli Lilly's Alzheimer's Drug Faces UK Agen...
08/26/2024 12:45:22

The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent ...

biogens-alzheimers-drug-secures-uk-approval-but-an-independent-agency-does-not-recommend-reimbursement
Biogen's Alzheimer's Drug Secures UK Appro...
08/22/2024 17:45:50

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild co...

eisai-and-biogens-alzheimers-drug-leqembi-receives-first-european-approval-in-great-britain
Eisai and Biogen's Alzheimer's Drug Leqemb...
08/22/2024 09:13:37

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...

cracking-the-code-understanding-analyst-reviews-for-biogen
Cracking The Code: Understanding Analyst R...
08/19/2024 13:00:41

needham-reiterates-buy-on-biogen-maintains-285-price-target
Needham Reiterates Buy on Biogen, Maintain...
08/19/2024 09:31:20

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.

how-is-the-market-feeling-about-biogen
How Is The Market Feeling About Biogen?
08/09/2024 19:45:24

mizuho-maintains-outperform-on-biogen-lowers-price-target-to-251
Mizuho Maintains Outperform on Biogen, Low...
08/06/2024 11:19:51

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $277 to $251.

truist-securities-reiterates-buy-on-biogen-lowers-price-target-to-302
Truist Securities Reiterates Buy on Biogen...
08/05/2024 13:43:51

Truist Securities analyst Srikripa Devarakonda reiterates Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $...

needham-maintains-buy-on-biogen-lowers-price-target-to-285
Needham Maintains Buy on Biogen, Lowers Pr...
08/05/2024 10:12:38

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $288 to $285.

rbc-capital-maintains-outperform-on-biogen-raises-price-target-to-292
RBC Capital Maintains Outperform on Biogen...
08/02/2024 19:46:44

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $282 to...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION